Convert Pharmaceuticals develops prodrugs that are inert upon administration to patients, but transform into potent anti-cancer agents upon entering tumors. Convert’s proprietary insights in both the tumor microenvironment and specific biomarkers as well as the chemical design of prodrugs guide the development of these next-generation therapeutics.
Several academic centers have collaborated with Convert Pharmaceuticals to expand knowledge about its main compound, CP-506, and the biomarkers that will enable selection of patients that would most benefit from the hypoxia activated prodrug under investigation. These research efforts have recently led to three key......
We are glad to share that the Clinical Trial Application prepared by Convert Pharmaceuticals for the Phase 1 Clinical Trial of CP-506 (NCT04954599) has been approved by both the Competent Authorities and the reference Ethical Committee in the Netherlands. The prodrug will be tested in......
Convert Pharmaceuticals, a Belgian biotech company developing anti-cancer therapeutics, has obtained very promising pre-clinical results with CP-506 drug, a new and improved Hypoxia Activated Prodrug. The company is finalising its Clinical Trial Application to obtain regulatory approval for the launch of its tumor agnostic Phase......